Inside the research
DexCom, Inc.
DXCM Research profile · latest available data
Price overview
$86.62
▼ -0.85 (-1.0%)
| 52w hi | $92.34 |
|---|---|
| 52w lo | $54.84 |
| Vol | 1.89M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.49
| Short | +0.36 |
|---|---|
| Medium | +0.62 |
| Long | +0.51 |
computed 2026-09-27
Key fundamentals
DexCom, Inc.
Healthcare · Medical Devices
| Market cap | $32.69B |
|---|---|
| Enterprise value | $32.14B |
| Trailing P/E | 34.24x |
| Forward P/E | 27.73x |
| EV / EBITDA | 22.90x |
| P / S (ttm) | 6.58x |
| Profit margin | 20.1% |
| Return on equity | 38.5% |
| Revenue growth | +13.1% |
| Earnings growth | +43.6% |
| Debt / equity | 53.35 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.29 | |
| Sector | +0.08 | |
| Technical | +0.30 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Risk Metrics
| Beta vs SPX | 0.94 |
|---|---|
| Corr SPX | 0.37 |
| Annual vol | 41.2% |
| Annual ret | +18.8% |
| Sharpe | 0.46 |
| Max DD | -39.6% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $83.54 |
|---|---|
| High / Low | $112.00 / $65.00 |
| Median | $80.00 |
| Analysts | 24 |
| Strong Buy | 4 | |
|---|---|---|
| Buy | 20 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 1 |
Recent rating actions
| 2026-05-04 | Citigroup | → Buy |
| 2026-05-01 | TD Cowen | → Buy |
| 2026-05-01 | Canaccord Genuity | → Buy |
| 2026-05-01 | Barclays | → Underweight |
| 2026-03-11 | Citigroup | → Buy |
| 2026-03-09 | BTIG | → Buy |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-30 | Earnings Release, Exhibits | read |
| 2026-05-28 | Shareholder Vote | read |
| 2026-05-15 | Reg FD Disclosure, Other Material Event | read |
| 2026-04-30 | Earnings Release, Exhibits | read |
| 2026-03-02 | Officer / Director Change, Exhibits | read |
| 2026-02-26 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-02-12 | Earnings Release, Exhibits | read |
| 2026-01-12 | Earnings Release, Exhibits | read |
| 2025-12-22 | Officer / Director Change, Exhibits | read |
| 2025-10-30 | Earnings Release, Exhibits | read |
| 2025-10-27 | Officer / Director Change, Reg FD Disclosure… | read |
| 2025-09-16 | Officer / Director Change | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | AUGUSTINOS NICHOLAS | Gift | 1.07K | — | |
| 2026-08-12 | Heller Bridgette P | Sell | 1.01K | $89.35K | |
| 2026-08-03 | FOLETTA MARK G | Sell | 2.00K | $170.64K | |
| 2026-07-31 | FOLETTA MARK G | Sell | 2.00K | $160.00K | |
| 2026-07-20 | SAYER KEVIN R | Executive Chair | Sell | 26.76K | $2.04M |
| 2026-07-15 | Brown Michael Jon | EVP Chief Legal Complianc | Sell | 1.70K | $126.51K |
| 2026-07-06 | SAYER KEVIN R | Executive Chair | Sell | 26.76K | $1.93M |
| 2026-06-15 | Brown Michael Jon | EVP Chief Legal Complianc | Sell | 1.70K | $128.44K |
| 2026-06-15 | FOLETTA MARK G | Sell | 3.80K | $281.65K | |
| 2026-06-15 | FOLETTA MARK G | Sell | 199 | $14.89K |
Flow & Concentration
| Insider 180d net | -$5.66M |
|---|---|
| Insider buys / sells | 0 / 11 |
| Insider bias | Sellers |
| 13F holders | 9 |
| Top-5 share | 94.2% |
| HHI | 2,316 (moderate) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| AQR Capital Management | $218.06M | 3.24M |
| Fidelity / FMR LLC | $127.51M | 1.89M |
| Renaissance Technologies | $109.83M | 1.63M |
| Citadel Advisors | $84.21M | 90.14M |
| State Street Corp | $30.08M | 32.33M |
| Bridgewater Associates | $27.00M | 400.93K |
| Capital Research / Capital World | $4.71M | 5.05M |
| Millennium Management | $2.92M | 3.12M |
| T. Rowe Price Group | $150.78K | 2.24M |
As of 2026-06-30
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $4.66B | +38.5% | |
| Gross profit | $2.29B | +49.6% | |
| Operating income | $911.80M | +24.9% | |
| Net income | $576.20M | +3.1% | |
| Cash from ops | $748.50M | +61.4% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $87.38 | $87.64 | $86.36 | $86.62 | 1.89M |
| Sep 24 | $87.68 | $88.00 | $86.88 | $87.47 | 2.14M |
| Sep 23 | $89.50 | $90.05 | $87.36 | $87.73 | 3.67M |
| Sep 22 | $89.12 | $90.39 | $88.18 | $89.53 | 7.30M |
| Sep 21 | $88.83 | $89.68 | $88.33 | $89.17 | 3.52M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →